Evercore ISI lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) from an outperform rating to an in-line rating in a research note issued to investors on Friday morning, Marketbeat Ratings reports. They currently have $14.00 price objective on the biotechnology company’s stock.
BCRX has been the subject of several other reports. Cantor Fitzgerald reissued an overweight rating on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. StockNews.com cut BioCryst Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, May 12th. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $14.00 and gave the company an equal weight rating in a report on Friday. Royal Bank of Canada cut their price target on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a sector perform rating on the stock in a research note on Tuesday, April 12th. Finally, Piper Sandler reduced their target price on BioCryst Pharmaceuticals from $24.00 to $19.00 in a research note on Thursday, May 5th. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $17.78.
BioCryst Pharmaceuticals Stock Performance
Shares of BCRX stock opened at $14.05 on Friday. The stock has a 50 day moving average price of $10.79 and a 200 day moving average price of $12.78. BioCryst Pharmaceuticals has a 52-week low of $7.61 and a 52-week high of $19.99. The firm has a market capitalization of $2.61 billion, a P/E ratio of -12.22 and a beta of 2.20.
Institutional Trading of BioCryst Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Semmax Financial Advisors Inc. boosted its position in BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,352 shares in the last quarter. Strs Ohio purchased a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. Fairfield Bush & CO. purchased a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $34,000. CWM LLC purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth approximately $47,000. Finally, Lazard Asset Management LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $57,000. Hedge funds and other institutional investors own 63.86% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
- Get a free copy of the StockNews.com research report on BioCryst Pharmaceuticals (BCRX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.